Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820612 · ClinicalTrials.gov registry record · Phase 4
Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients
A Phase 4 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 4
- Development phase
- 602
- Enrollment target
NCT00820612 is a Phase 4 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 602 participants.
The verdict
NCT00820612, a Phase 4 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 602 participants
- Enrollment target
Study Summary
Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of disorders of the pancreas and bile duct. Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered rectally, can reduce the risk of pancreatitis after ERCP. This study is intended to definitively determine whether rectally administered indomethacin (a non-steroidal antiinflammatory drug)is effective at preventing pancreatitis after ERCP.
Interventions
- DRUG Indomethacin
- OTHER Placebo suppositories
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820612
The ClinicalTrials.gov registry entry for NCT00820612 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indomethacin is the first listed.
NCT00820612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00820612 about?
NCT00820612 is a clinical study titled "Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients". Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of disorders of the pancreas and bile duct. Preliminary data has shown that non-steroidal antiinflammatory drugs, when ad...
What is the current status of trial NCT00820612?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 602 participants. The study started on 2009-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00820612?
The interventions under investigation include: Indomethacin (DRUG), Placebo suppositories (OTHER).
Who is sponsoring clinical trial NCT00820612?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.